M+QuickMedCalc
Educational reference only. Not a diagnostic tool. See full disclaimer.
Gastroenterology & HepatologyAIMS65 Score

AIMS65 Score Calculator for Upper GI Bleeding

Calculate the original Saltzman 2011 AIMS65 score from albumin, INR, altered mental status, systolic blood pressure, and age, with exact thresholds and historical mortality context.

Content updated: View sources

QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.

Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.

Enter the initial AIMS65 assessment

All seven fields begin blank. Measured values are compared exactly; missing evidence never becomes zero points.

The original model used patients admitted from emergency departments with acute upper GI bleeding; this non-scoring gate contributes zero points. [1]

A — Serum albumin

Albumin <3.0 g/dL (equivalently <30 g/L) contributes 1 point. Equality does not score. Changing the selected unit clears the entered value. [1]

INR >1.5 contributes 1 point; INR 1.5 does not. [1]

Systolic BP ≤90 mmHg contributes 1 point; 90 is included. [1]

The original definition was GCS <14 or a physician designation of disoriented, lethargy, stupor, or coma. Both pathways still contribute only 1 point; GCS 14 alone does not satisfy GCS <14. [1]

Age older than 65 years (>65) contributes 1 point; age 65 does not. [1]

Select the source assessment context and complete all five criteria to display the AIMS65 total, original mortality-risk grouping, historical exact-score cohort context, and complete point audit.

About

This AIMS65 Score calculator reproduces the original Saltzman 2011 five-factor model for patients admitted from emergency departments with acute upper GI bleeding. It uses values available at initial evaluation and does not require endoscopic findings. [1]

The original outcome was in-hospital mortality, with additional associations with length of stay and hospitalization cost. It was not derived as a bleeding-source, rebleeding, endoscopic-intervention, discharge, ICU-admission, or treatment rule. [1]

Formula

AIMS65 = albumin <3.0 g/dL + INR >1.5 + source-defined altered mental status + systolic BP ≤90 mmHg + age >65 years
Each present criterion contributes 1 point; maximum = 1 + 1 + 1 + 1 + 1 = 5

Interpretation

AIMS65 scoreDerivation cohort exact-score mortalityValidation cohort exact-score mortality
00.3%0.3%
11.2%1.2%
23.6%2.8%
39.8%8.5%
421.8%15.1%
531.8%24.5%

These are historical cohort observations for patients with exactly each score, not an individual probability or treatment/disposition instruction. [1]

Validation cohort cumulative cutoff groups

Cumulative groupMortality in that cutoff group
AIMS65 >=13.2%
AIMS65 >=25.3%
AIMS65 >=310.3%
AIMS65 >=416.5%
AIMS65 524.5%

These are cumulative cutoff groups, not exact-score rates: 5.3% describes score ≥2, not exact score 2; 10.3% describes score ≥3, not exact score 3; and 16.5% describes score ≥4, not exact score 4. [1]

AIMS65 versus Glasgow-Blatchford

AIMS65 was developed primarily around in-hospital mortality. Glasgow-Blatchford focuses on hospital intervention or treatment-related outcomes and identification of very-low-risk patients. In the 3,012-patient 2017 international study, GBS performed better for intervention/death and endoscopic-treatment prediction, while AIMS65 discriminated mortality better than GBS. These are distinct tasks, and neither score universally replaces the other. [2]

Why AIMS65 0 is not a discharge rule

In that multicenter study, 25% of patients with AIMS65 0 still had the composite of hospital intervention or death. The 2019 International Consensus Group suggested against using AIMS65 to identify very-low-risk patients who might avoid hospitalization or inpatient endoscopy. ACG 2021 and ESGE 2021 instead use GBS 0–1 or ≤1 as their example of the very-low-risk outpatient framework. [2, 3, 4, 5]

Original study scale and limits

The model used 29,222 derivation admissions from 2004–2005 and 32,504 validation admissions from 2006–2007 across 187 U.S. hospitals. AUROC was 0.80 (95% CI 0.78–0.81) in derivation and 0.77 (95% CI 0.75–0.79) in validation. The database did not contain rebleeding, endoscopic, or transfusion-requirement outcomes. [1]

What this score cannot decide

AIMS65 does not diagnose the bleeding source or independently determine discharge, admission, ICU placement, transfusion, medication, reversal, endoscopy timing, embolization, surgery, or other treatment. Hemodynamic instability and active severe bleeding require immediate clinical assessment and must not wait for an online score.

References

  1. Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc. 2011;74(6):1215–1224. PMID 21907980. DOI 10.1016/j.gie.2011.06.024.
  2. Stanley AJ, Laine L, Dalton HR, et al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ. 2017;356:i6432. PMID 28053181. PMCID PMC5217768. DOI 10.1136/bmj.i6432.
  3. Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med. 2019;171(11):805–822. PMID 31634917. PMCID PMC7233308. DOI 10.7326/M19-1795.
  4. Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. Am J Gastroenterol. 2021;116(5):899–917. PMID 33929377. DOI 10.14309/ajg.0000000000001245.
  5. Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy Guideline – Update 2021. Endoscopy. 2021;53(3):300–332. PMID 33567467. DOI 10.1055/a-1369-5274.

FAQ

Related Calculators

Disclaimer

Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.